AU2001294624A1 - Recombinant adenovirus vectors that are replication-competent in tert-expressing cells - Google Patents

Recombinant adenovirus vectors that are replication-competent in tert-expressing cells

Info

Publication number
AU2001294624A1
AU2001294624A1 AU2001294624A AU9462401A AU2001294624A1 AU 2001294624 A1 AU2001294624 A1 AU 2001294624A1 AU 2001294624 A AU2001294624 A AU 2001294624A AU 9462401 A AU9462401 A AU 9462401A AU 2001294624 A1 AU2001294624 A1 AU 2001294624A1
Authority
AU
Australia
Prior art keywords
competent
replication
tert
expressing cells
recombinant adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294624A
Inventor
Konstantin Doronin
Mohan Kuppuswamy
Ann E. Tollefson
Karoly Toth
William S. M. Wold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University filed Critical St Louis University
Publication of AU2001294624A1 publication Critical patent/AU2001294624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001294624A 2000-09-20 2001-09-20 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells Abandoned AU2001294624A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23387200P 2000-09-20 2000-09-20
US60/233,872 2000-09-20
US09/956,335 2001-09-19
US09/956,335 US6627190B2 (en) 1999-07-12 2001-09-19 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
PCT/US2001/029550 WO2002024640A2 (en) 2000-09-20 2001-09-20 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells

Publications (1)

Publication Number Publication Date
AU2001294624A1 true AU2001294624A1 (en) 2002-04-02

Family

ID=26927320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294624A Abandoned AU2001294624A1 (en) 2000-09-20 2001-09-20 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells

Country Status (4)

Country Link
US (1) US6627190B2 (en)
EP (1) EP1326839A2 (en)
AU (1) AU2001294624A1 (en)
WO (1) WO2002024640A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US7589069B1 (en) * 1999-07-12 2009-09-15 Saint Louis University Replication-competent anti-cancer vectors
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
CN1195056C (en) * 2001-07-12 2005-03-30 钱其军 Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US7598362B2 (en) * 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
US7094399B2 (en) * 2002-05-08 2006-08-22 Intronn, Inc. Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20040213764A1 (en) * 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7598077B2 (en) * 2003-06-05 2009-10-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for enhancing differential expression
ATE420160T1 (en) 2003-06-18 2009-01-15 Genelux Corp MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
US7815902B2 (en) * 2003-07-09 2010-10-19 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
EP1644382B1 (en) * 2003-07-11 2008-03-05 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) * 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
KR100792183B1 (en) * 2006-05-29 2008-01-07 울산대학교 산학협력단 Synthetic Human Telomerase Reverse Transcriptase Promoter Enhancing Gene Expression
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
ES2617598T3 (en) 2008-01-25 2017-06-19 Multivir Inc. P53 biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells

Also Published As

Publication number Publication date
WO2002024640A2 (en) 2002-03-28
EP1326839A2 (en) 2003-07-16
US20020028785A1 (en) 2002-03-07
US6627190B2 (en) 2003-09-30
WO2002024640A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU2001294624A1 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
AU1340000A (en) Novel adenoviral vector and methods for making and using the same
AU3635899A (en) Recombinant adenovirus gene transfer vector
IL161584A (en) Recombinant adenovirus host cells and compositions containing same and uses thereof
AU4255397A (en) Chimpanzee adenovirus vectors
AU2002327380A1 (en) Cells and methods for propagating adenoviral vectors
AU5882801A (en) Novel recombinant adenovirus vector with relieved side effects
AU2035601A (en) Load cell
AU7435500A (en) Adenoviral vectors
AUPQ520600A0 (en) Improvements in electrolysis cells
AU2001229728A1 (en) Replication deficient adenovirus vectors
AU4942499A (en) Load cell
AU1741000A (en) Recombinant factor viii binding peptides
GB2345402B (en) Improvements in loudspeakers
AU2001281464A1 (en) Recombinant proteins containing repeating units
AU2145300A (en) Adenoviral vectors
AU1092500A (en) Recombinant e1a deleted adenoviral vectors
AU2350997A (en) Novel adenoviral vector for transferring human genes in vivo
AU2001237215A1 (en) Genetically modified fibroblast cell
AU2002215747A1 (en) Pixel cell architecture
AU3375500A (en) Adenoviral vectors, proteins and methods for their use
AU5931600A (en) Lcat recombinant cell line compositions and methods
IL128742A0 (en) Recombinant adenovirus vector
AU4070499A (en) Adenoviral vectors with tandem fiber proteins
AU2002211654A1 (en) Minimal adenoviral vector and recombinant vaccines based thereon